This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Lusutrombopag oral

Updated 2 Feb 2023 | Platelet disorders


Oral formulation of lusutrombopag.

Drugs List

  • lusutrombopag 3mg tablets
  • MULPLEO 3mg film coated tablets
  • Therapeutic Indications


    Severe thrombocytopenia with chronic liver disease

    Treatment of severe thrombocytopenia in adult patients with chronic liver disease undergoing invasive procedures.



    3mg once daily for 7 days.

    The procedure should be performed from day 9 after the start of treatment.

    Additional Dosage Information

    Missed doses
    If a dose is missed it should be taken as soon as possible. A double dose should not be taken.


    Children under 18 years

    Precautions and Warnings

    Females of childbearing potential
    Weight below 45kg
    History of thromboembolic disorder
    History of thrombosis
    Portal vein obstruction
    Severe hepatic impairment - Child-Pugh score greater than or equal to 10
    Thromboembolic disorder

    Monitor platelets before starting and during treatment
    Perform liver function tests before commencing therapy and during therapy
    Monitor for signs and symptoms of thrombosis
    Monitor for signs of hepatic injury
    Monitor patients at risk for signs & symptoms of thromboembolism
    Treatment should be for a maximum period of 7 days
    Female: Ensure adequate contraception during treatment

    Monitor patients with thrombosis or thromboembolism, with a history of thrombosis or thromboembolism, with absence of hepatopetal blood flow in the main trunk of the portal vein, or patients with congenital coagulopathy.

    Lusutrombopag should only be used in patients with severe hepatic impairment if the expected benefit outweighs the expected risk.

    Monitor patients with severe hepatic impairment for early signs of worsening or new onset hepatic encephalopathy, ascites, and thrombotic or bleeding tendency, through monitoring of liver function tests, tests used for assessing clotting status and through imaging of portal vasculature as needed.

    Discontinue lusutrombopag if platelet counts are 50 x 10 to the power of 9 per litre or greater, as a result of a 20 x 10 to the power of 9 per litre increase from baseline.

    The efficacy and safety of lusutrombopag have not been established when administered before lapartotomy, thoracotomy, open-heart surgery, craniotomy or excision of organs.

    Pregnancy and Lactation


    Lusutrombopag is contraindicated during pregnancy.

    The manufacturer does not recommend using lusutrombopag during pregnancy. At the time of writing there is limited published information regarding the use of lusutrombopag during pregnancy. Potential risks are unknown.


    Lusutrombopag is contraindicated during breastfeeding.

    Use of lusutrombopag when breastfeeding is contraindicated by the manufacturer. Animal data reports levels of lusutrombopag in the breast milk, however presence in human breast milk and the effect on exposed infants are unknown.

    Side Effects

    Portal vein thrombosis


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: December 2019

    Reference Sources

    Summary of Product Characteristics: Mulpleo 3mg film-coated tablets. Shionogi Ltd. Revised February 2019.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.